Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) were up 4.9% during trading on Tuesday. The company traded as high as $0.4403 and last traded at $0.42. 3,036 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 6,771 shares. The stock had previously closed at $0.4005.
Avenue Therapeutics Stock Performance
The business’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.39. The company has a market cap of $1.42 million, a P/E ratio of 0.02 and a beta of -0.23.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for acute and other serious medical conditions. The company is headquartered in the United States and trades on the Nasdaq under the symbol ATXI.
Avenue’s primary product candidate has been intravenous tramadol, an investigational formulation intended to provide short-term management of acute postoperative pain in adults who require an opioid analgesic in a medically supervised setting.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
